Financial Performance - The company's operating revenue for Q3 2023 was ¥89,803,650.07, a decrease of 14.34% compared to the same period last year[5] - The net profit attributable to shareholders for Q3 2023 was ¥26,118,923.20, an increase of 0.80% year-on-year[5] - The net profit after deducting non-recurring gains and losses was ¥25,534,715.87, up 1.04% from the previous year[5] - Total operating revenue for Q3 2023 was CNY 283,171,670.70, a decrease of 10.43% compared to CNY 316,172,855.02 in Q3 2022[15] - Net profit for Q3 2023 was CNY 71,926,596.85, representing a decline of 13.14% from CNY 82,776,451.87 in Q3 2022[16] - The company reported a decrease in total profit to CNY 82,873,833.84, down 13.56% from CNY 95,882,170.76 in Q3 2022[16] - Basic and diluted earnings per share for Q3 2023 were both CNY 1.19, down from CNY 1.62 in the same period last year[17] Assets and Equity - The total assets at the end of the reporting period reached ¥1,301,262,008.78, an increase of 130.11% compared to the end of the previous year[5] - The equity attributable to shareholders increased by 159.31% to ¥1,216,271,943.79 compared to the end of the previous year[5] - As of September 30, 2023, the total current assets amounted to ¥1,160,705,442.85, a significant increase from ¥446,186,172.31 at the beginning of the year, reflecting a growth of approximately 160%[13] - Total assets increased to ¥1,301,262,008.78 from ¥565,484,619.74, representing an increase of approximately 130%[14] - The company's equity increased significantly, with total equity rising to ¥1,216,271,943.79 from ¥469,037,317.24, marking an increase of approximately 159%[14] Cash Flow - The cash flow from operating activities for the year-to-date was ¥37,908,614.75, a decrease of 27.64% compared to the same period last year[5] - Cash flow from operating activities generated a net amount of CNY 37,908,614.75, a decrease of 27.61% compared to CNY 52,391,177.85 in Q3 2022[17] - The net cash flow from financing activities was ¥673,783,368.80, a dramatic increase of 25,759.57% due to successful fundraising efforts[10] - Net cash flow from financing activities amounted to ¥673,783,368.80, a significant increase compared to a net outflow of ¥2,625,856.00 in the previous period[18] - Total cash and cash equivalents at the end of the period reached ¥918,685,946.31, up from ¥225,158,250.43 at the end of the previous period[18] - The net increase in cash and cash equivalents for the period was ¥679,447,820.66, compared to an increase of ¥41,444,655.47 in the previous period[18] Expenses and Costs - Research and development expenses increased by 33.87% to ¥12,416,146.91, reflecting the company's commitment to enhancing R&D capabilities[9] - Research and development expenses increased to CNY 12,416,146.91, up 33.00% from CNY 9,275,074.86 in the previous year[15] - Total operating costs decreased to CNY 201,984,375.33, down 10.14% from CNY 224,763,134.15 in the previous year[15] - The company reported a decrease in government subsidies received, with other income dropping by 61.78% to ¥2,882,331.50 compared to the previous year[9] - Other income decreased to CNY 2,882,331.50 from CNY 7,541,728.71 in the previous year, indicating a decline of 61.73%[15] - The company experienced a reduction in financial expenses, reporting a net financial income of CNY 11,026,073.54 compared to CNY 10,531,352.33 in the previous year[15] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 17,547, with no preferred shareholders having voting rights[12] - The largest shareholder, Zhejiang Haisen Holdings, holds 32.96% of the shares, followed by Wang Shiyue with 19.96%[11] Inventory and Liabilities - The company reported an increase in inventory to ¥158,104,654.48 from ¥142,646,529.87, reflecting a growth of about 11%[13] - The accounts payable increased to ¥23,234,923.18 from ¥19,037,512.88, indicating a rise of approximately 22%[14] - The total liabilities decreased to ¥84,990,064.99 from ¥96,447,302.50, showing a reduction of about 12%[14] Future Plans - The company has plans for market expansion and new product development, although specific details were not disclosed in the provided content[12] Audit Information - The company did not undergo an audit for the third quarter report[19]
海森药业(001367) - 2023 Q3 - 季度财报